This trial is active, not recruiting.

Condition solid tumor
Treatment liposomal paclitaxel
Phase phase 1
Sponsor Nanjing Sike Pharmaceutical Co., Ltd.
Start date April 2009
End date October 2009
Trial size 15 participants
Trial identifier NCT00881101, LPS- PH I -01-2009


The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Liposomal paclitaxel
liposomal paclitaxel
All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.

Primary Outcomes

maximum tolerated dose
time frame: 6 months

Secondary Outcomes

dose limiting toxicity
time frame: 6 months

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: 1. Age: from 18 to 70 2. Patients with solid tuomors at advanced stage must be histologically or cytologically confirmed ,and be suitable for treating with Paclitaxel Liposome solo 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS)is from 0 to 2 4. Patients who are expected to live at least 3 months 5. Laboratory tests before the study: white blood count (WBC)≥4,000/mm³,absolute neutrophil count (ANC) ≥1,500/mm³, platelet count ≥100,000/mm³, hemoglobin≥9.0 g/dL, aspartate aminotransferase AST (sGOT) and alanine aminotransferase ALT(sGPT)≤2.5 times of normal value upper limit,serum creatinine≤1.0 time of normal value upper limit,total bilirubin≤1.5 times of normal value upper limit 6. Not using chemotherapeutics (including test drug)before the study trial at least 4 weeks 7. No obvious functional disturbance diseases of internal organs 8. Complying with the study protocol 9. Sign informed consent 10. No Previous anaphylactic reaction to hormone Exclusion Criteria: 1. Allergy to any medication or foods; History of hypersensitivity reactions to the conventional dosage form of paclitaxel or correlate excipients 2. Active uncontrolled central nervous system metastasis 3. Severe complications that obviously influence the compliance of patients 4. Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria 5. Taking other study medications or participating other clinical trial within 4w 6. Having radiation therapy or operation within 4w 7. Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin) 8. Pregnant or lactant women; fertile patients not using effective contraception during study 9. No chief organ functional disturbance or diseases: - abnormal liver and renal functions - myocardial infarction - active heart disease - neuropathy or mental diseases including dementia or epilepsy - blind、deaf、dumb or extremity disability - known infection - active diffuse intravascular coagulation 10. Others whom researchers regard not eligible for the study.

Additional Information

Official title Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors
Principal investigator Jin Li, Dr.
Description There are clinical trials show that paclitaxel is common option for the treatment of solid tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is designed to find the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese cancer patients.
Trial information was received from ClinicalTrials.gov and was last updated in April 2009.
Information provided to ClinicalTrials.gov by Nanjing Sike Pharmaceutical Co., Ltd..